Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows – The Cancer Letter
Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? […]